Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00266279
Status:
COMPLETED
Last Update Posted:
2020-09-03
First Post:
2005-12-15
Brief Title:
Phase II Treatment Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
Sponsor:
University of Louisville
Organization:
University of Louisville
Study Overview
Official Title:
Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
Status:
COMPLETED
Status Verified Date:
2020-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II study will test the response rate of combined oxaliplatin and capecitabine treatment when administered at a given dose and schedule in patients with Head and Neck cancer for which there is no curative treatment
Detailed Description:
The optimal dose and schedule for the combined treatment with oxaliplatin and capecitabine have not been defined The aim of this Phase II study is to determine the response rate of combined oxaliplatin and capecitabine treatment at a given dose and schedule in patients with Head and Neck cancer for which there is no curative treatment
The study also aims to determine the qualitative and quantitative toxicity and reversibility of toxicity of the above combination and to evaluate any changes in performance status quality of life overall survival and progression-free survival
The study also aims to determine the qualitative and quantitative toxicity and reversibility of toxicity of the above combination and to evaluate any changes in performance status quality of life overall survival and progression-free survival
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None